Library Header Image
LSE Research Online LSE Library Services

Assessment of price and clinical benefit of cancer drugs in Canada, 2011-2020

Jenei, Kristina, Meyers, Daniel and Gyawali, Bishal (2023) Assessment of price and clinical benefit of cancer drugs in Canada, 2011-2020. JAMA network open, 6 (1). e2253438. ISSN 2574-3805

Full text not available from this repository.

Identification Number: 10.1001/jamanetworkopen.2022.53438


Cancer drug prices have increased exponentially in the past decade and several studies have demonstrated an increasing disconnect between clinical benefit and prices for cancer drugs approved by the US Food and Drug Administration or the European Medicines Agency.1,2 This disconnect seemed to exist even in the setting of central price negotiations in Italy.3 However, to our knowledge this has not been studied for Canada. This study examined the association between approval characteristics, clinical benefit, and prices for cancer drugs recommended for reimbursement in Canada by the Canadian Agency for Drug and Technology in Health (CADTH).

Item Type: Article
Additional Information: © 2023 The Author.
Divisions: Health Policy
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited: 27 Feb 2023 12:48
Last Modified: 09 Jun 2024 17:51

Actions (login required)

View Item View Item